JP2020512343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512343A5 JP2020512343A5 JP2019552983A JP2019552983A JP2020512343A5 JP 2020512343 A5 JP2020512343 A5 JP 2020512343A5 JP 2019552983 A JP2019552983 A JP 2019552983A JP 2019552983 A JP2019552983 A JP 2019552983A JP 2020512343 A5 JP2020512343 A5 JP 2020512343A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- heterocyclyl
- alkyl
- halo
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 130
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- -1 isooxazolyl Chemical group 0.000 claims description 80
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 79
- 150000002431 hydrogen Chemical class 0.000 claims description 67
- 125000001424 substituent group Chemical group 0.000 claims description 61
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000003386 piperidinyl group Chemical group 0.000 claims description 20
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 17
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 13
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 10
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 10
- 125000002393 azetidinyl group Chemical group 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 claims description 5
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 5
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 5
- 230000004545 gene duplication Effects 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims 52
- 239000008194 pharmaceutical composition Substances 0.000 claims 50
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- PIINXYKJQGMIOZ-UHFFFAOYSA-N 1,2-dipyridin-2-ylethane-1,2-dione Chemical compound C=1C=CC=NC=1C(=O)C(=O)C1=CC=CC=N1 PIINXYKJQGMIOZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 26
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- SJHNWSAWWOAWJH-MRXNPFEDSA-N Cc1nccc(-c2nc(C(Nc3c(N(CC4)C[C@@H]4O)nc4nc(N5CCOCC5)[o]c4c3)=O)c[o]2)c1 Chemical compound Cc1nccc(-c2nc(C(Nc3c(N(CC4)C[C@@H]4O)nc4nc(N5CCOCC5)[o]c4c3)=O)c[o]2)c1 SJHNWSAWWOAWJH-MRXNPFEDSA-N 0.000 description 1
- 0 OCCNc([s]c1c2)nc1nc(N1CCCCC1)c2NC(c1cccc(N2C*CC2)n1)=O Chemical compound OCCNc([s]c1c2)nc1nc(N1CCCCC1)c2NC(c1cccc(N2C*CC2)n1)=O 0.000 description 1
- GTKVXHNHLXCCTB-UHFFFAOYSA-N [1-[1-(2-methoxyethyl)-5-[2-(2-methylpyridin-4-yl)-2H-1,3-oxazol-3-yl]indazol-6-yl]piperidin-4-yl]methanamine Chemical compound COCCn1ncc2cc(N3C=COC3c3ccnc(C)c3)c(cc12)N1CCC(CN)CC1 GTKVXHNHLXCCTB-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023129903A JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741011785 | 2017-03-31 | ||
| IN201741011785 | 2017-03-31 | ||
| PCT/IB2018/052232 WO2018178947A2 (en) | 2017-03-31 | 2018-03-30 | Compounds and compositions for treating hematological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129903A Division JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512343A JP2020512343A (ja) | 2020-04-23 |
| JP2020512343A5 true JP2020512343A5 (enExample) | 2021-05-06 |
| JP7333136B2 JP7333136B2 (ja) | 2023-08-24 |
Family
ID=63677680
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552983A Active JP7333136B2 (ja) | 2017-03-31 | 2018-03-30 | 血液疾患を処置するための化合物及び組成物 |
| JP2023129903A Withdrawn JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129903A Withdrawn JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11419875B2 (enExample) |
| EP (2) | EP4252853A3 (enExample) |
| JP (2) | JP7333136B2 (enExample) |
| KR (3) | KR20250065441A (enExample) |
| CN (2) | CN120267671A (enExample) |
| AU (2) | AU2018242623B2 (enExample) |
| BR (1) | BR112019018991A2 (enExample) |
| CA (1) | CA3056893A1 (enExample) |
| DK (1) | DK3600270T3 (enExample) |
| EA (1) | EA201992322A3 (enExample) |
| ES (1) | ES2950764T3 (enExample) |
| FI (1) | FI3600270T3 (enExample) |
| HR (1) | HRP20230657T8 (enExample) |
| HU (1) | HUE062648T2 (enExample) |
| IL (4) | IL305150B2 (enExample) |
| LT (1) | LT3600270T (enExample) |
| MX (2) | MX389825B (enExample) |
| PH (1) | PH12019502138A1 (enExample) |
| PL (1) | PL3600270T3 (enExample) |
| PT (1) | PT3600270T (enExample) |
| RS (1) | RS64411B1 (enExample) |
| SG (1) | SG11201908171TA (enExample) |
| SI (1) | SI3600270T1 (enExample) |
| SM (1) | SMT202300236T1 (enExample) |
| WO (1) | WO2018178947A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3466955T (pt) | 2014-01-13 | 2021-01-29 | Aurigene Discovery Tech Ltd | Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro |
| AU2018242623B2 (en) | 2017-03-31 | 2024-05-02 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| WO2021004533A1 (zh) * | 2019-07-10 | 2021-01-14 | 南京明德新药研发有限公司 | 作为irak4和btk多靶点抑制剂的噁唑类化合物 |
| CN112480101B (zh) * | 2019-09-12 | 2022-11-25 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| CA3179378A1 (en) | 2020-04-07 | 2021-10-14 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
| AU2021321350A1 (en) * | 2020-08-03 | 2023-03-16 | Curis, Inc. | Compositions and methods for treating diseases and disorders |
| US20230414582A1 (en) * | 2020-11-18 | 2023-12-28 | Curis, Inc. | Methods of treating diseases and disorders |
| WO2022135338A1 (zh) * | 2020-12-25 | 2022-06-30 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
| WO2022156788A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 苯并咪唑化合物及其用途 |
| EP4319750A4 (en) * | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
| TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
| WO2023088435A1 (zh) * | 2021-11-19 | 2023-05-25 | 成都奥睿药业有限公司 | 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用 |
| CN118530221A (zh) | 2021-12-23 | 2024-08-23 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| WO1991017748A1 (de) | 1990-05-18 | 1991-11-28 | Hoechst Aktiengesellschaft | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| ATE391492T1 (de) | 1997-07-29 | 2008-04-15 | Alcon Lab Inc | Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat |
| EP1051167A1 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| AU2004236240C1 (en) | 2003-05-01 | 2010-11-04 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole compounds useful as kinase inhibitors |
| ATE556067T1 (de) | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| WO2004108133A2 (en) | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| JP2007525482A (ja) | 2003-10-07 | 2007-09-06 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
| WO2005107460A1 (en) | 2004-04-22 | 2005-11-17 | Bayer Cropscience Lp | Method and composition for controlling weeds |
| EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| TW200628159A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| CN101072775A (zh) * | 2004-12-17 | 2007-11-14 | 伊莱利利公司 | 新的mch受体拮抗剂 |
| CA2589695A1 (en) | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
| EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US7820821B2 (en) | 2006-02-10 | 2010-10-26 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
| GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| CN101437519A (zh) | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| WO2007121154A2 (en) | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| MX2009002377A (es) | 2006-09-07 | 2009-03-13 | Biogen Idec Inc | Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1. |
| WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CN101772500A (zh) * | 2007-06-14 | 2010-07-07 | 先灵公司 | 作为蛋白质激酶抑制剂的咪唑并吡嗪 |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| WO2009012312A1 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| US8399448B2 (en) | 2007-08-08 | 2013-03-19 | Merck Serono Sa | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
| EP2252617A1 (en) | 2008-02-13 | 2010-11-24 | CGI Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| EP2311842A3 (en) * | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| JP2012509274A (ja) | 2008-11-19 | 2012-04-19 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害薬 |
| EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| WO2010072599A1 (en) | 2008-12-23 | 2010-07-01 | F. Hoffmann-La Roche Ag | Dihydropyridone ureas as p2x7 modulators |
| WO2010144909A1 (en) * | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
| BR112012003661A2 (pt) * | 2009-08-19 | 2017-04-25 | Ambit Biosciences Corp | "compostos de biarila e métodos de uso dos mesmos." |
| WO2011046954A1 (en) | 2009-10-13 | 2011-04-21 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| EP2560962B1 (en) | 2010-04-22 | 2015-05-20 | Janssen Pharmaceutica NV | Indazole compounds useful as ketohexokinase inhibitors |
| US20130053382A1 (en) | 2010-04-30 | 2013-02-28 | Sunil Paliwal | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| KR101995013B1 (ko) | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| MX344521B (es) | 2010-11-19 | 2016-12-19 | Ligand Pharm Inc | Aminas heterociclicas y sus usos. |
| BR112013015460B1 (pt) | 2010-12-20 | 2022-01-25 | Merck Serono S.A. | Derivados de indazolil triazol, kit, e composição farmacêutica |
| WO2012142125A2 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
| WO2013042137A1 (en) * | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| CA2851155C (en) * | 2011-10-14 | 2021-02-23 | Ambit Biosciences Corporation | Heterocyclic compounds and methods of use thereof |
| EP2768509B1 (en) | 2011-10-20 | 2017-03-22 | Glaxosmithkline LLC | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
| WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| US9334249B2 (en) | 2012-11-03 | 2016-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
| US9168257B2 (en) | 2013-05-22 | 2015-10-27 | Children's Hospital Medical Center | Combination therapy for MDS |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US10160753B2 (en) | 2014-01-10 | 2018-12-25 | Aurigene Discovery Technologies Limited | Indazole compounds as IRAK4 inhibitors |
| PT3466955T (pt) | 2014-01-13 | 2021-01-29 | Aurigene Discovery Tech Ltd | Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro |
| CA2938719A1 (en) | 2014-02-06 | 2015-08-13 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| AU2015275730A1 (en) | 2014-06-20 | 2016-12-15 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as IRAK4 inhibitors |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| BR112018000635A2 (pt) * | 2015-07-15 | 2018-09-18 | Aurigene Discovery Tech Ltd | compostos aza substituídos como inibidores irak-4 |
| HK1249509A1 (zh) | 2015-07-15 | 2018-11-02 | Aurigene Discovery Technologies Limited | 作为irak-4抑制剂的吲唑及氮杂吲唑化合物 |
| CA2993661A1 (en) | 2015-08-04 | 2017-02-09 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
| EP3532164A4 (en) | 2016-10-28 | 2020-10-07 | Children's Hospital Medical Center | TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED |
| AU2018242623B2 (en) | 2017-03-31 | 2024-05-02 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| KR102697663B1 (ko) | 2017-10-31 | 2024-08-21 | 쿠리스 인코퍼레이션 | 혈액학적 장애를 치료하기 위한 화합물 및 조성물 |
-
2018
- 2018-03-30 AU AU2018242623A patent/AU2018242623B2/en active Active
- 2018-03-30 LT LTEPPCT/IB2018/052232T patent/LT3600270T/lt unknown
- 2018-03-30 JP JP2019552983A patent/JP7333136B2/ja active Active
- 2018-03-30 IL IL305150A patent/IL305150B2/en unknown
- 2018-03-30 EA EA201992322A patent/EA201992322A3/ru unknown
- 2018-03-30 CN CN202510475412.9A patent/CN120267671A/zh active Pending
- 2018-03-30 SI SI201830946T patent/SI3600270T1/sl unknown
- 2018-03-30 MX MX2019011158A patent/MX389825B/es unknown
- 2018-03-30 EP EP23173240.5A patent/EP4252853A3/en active Pending
- 2018-03-30 CA CA3056893A patent/CA3056893A1/en active Pending
- 2018-03-30 KR KR1020257014711A patent/KR20250065441A/ko active Pending
- 2018-03-30 ES ES18777745T patent/ES2950764T3/es active Active
- 2018-03-30 HU HUE18777745A patent/HUE062648T2/hu unknown
- 2018-03-30 FI FIEP18777745.3T patent/FI3600270T3/fi active
- 2018-03-30 CN CN201880022870.5A patent/CN110691589A/zh active Pending
- 2018-03-30 DK DK18777745.3T patent/DK3600270T3/da active
- 2018-03-30 HR HRP20230657TT patent/HRP20230657T8/hr unknown
- 2018-03-30 KR KR1020197032104A patent/KR102633530B1/ko active Active
- 2018-03-30 IL IL293783A patent/IL293783B2/en unknown
- 2018-03-30 RS RS20230544A patent/RS64411B1/sr unknown
- 2018-03-30 BR BR112019018991-2A patent/BR112019018991A2/pt active Search and Examination
- 2018-03-30 SM SM20230236T patent/SMT202300236T1/it unknown
- 2018-03-30 PT PT187777453T patent/PT3600270T/pt unknown
- 2018-03-30 US US16/498,866 patent/US11419875B2/en active Active
- 2018-03-30 PL PL18777745.3T patent/PL3600270T3/pl unknown
- 2018-03-30 IL IL316364A patent/IL316364A/en unknown
- 2018-03-30 WO PCT/IB2018/052232 patent/WO2018178947A2/en not_active Ceased
- 2018-03-30 EP EP18777745.3A patent/EP3600270B1/en active Active
- 2018-03-30 KR KR1020247003678A patent/KR20240019391A/ko not_active Ceased
- 2018-03-30 SG SG11201908171T patent/SG11201908171TA/en unknown
- 2018-03-30 IL IL269536A patent/IL269536B/en unknown
-
2019
- 2019-09-18 PH PH12019502138A patent/PH12019502138A1/en unknown
- 2019-09-19 MX MX2022001343A patent/MX2022001343A/es unknown
-
2022
- 2022-06-29 US US17/853,299 patent/US20220339161A1/en active Pending
-
2023
- 2023-08-09 JP JP2023129903A patent/JP2023154005A/ja not_active Withdrawn
-
2024
- 2024-06-11 AU AU2024203943A patent/AU2024203943A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512343A5 (enExample) | ||
| US20230346927A1 (en) | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | |
| CA2984259C (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| CN107857755B (zh) | 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物 | |
| JP2021501145A5 (enExample) | ||
| JP6342393B2 (ja) | 置換型ピラゾロン化合物及び使用方法 | |
| RU2665036C2 (ru) | Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения | |
| CA2351725A1 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
| JP2006502112A5 (enExample) | ||
| MX2010012290A (es) | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. | |
| TW201249823A (en) | Tetrasubstituted cyclohexyl compounds as kinase inhibitors | |
| RU2672910C2 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| JP2018515555A5 (enExample) | ||
| WO2020100027A1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| JP2004506736A5 (enExample) | ||
| IL305843B1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors | |
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| JP2018532788A5 (enExample) | ||
| WO2014022128A1 (en) | Pi3 kinase modulators and methods of use | |
| JP2008517042A5 (enExample) | ||
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| US12202816B2 (en) | Compounds as NADPH oxidase inhibitors | |
| CN1980912A (zh) | 吡唑衍生物 | |
| EP4076462A1 (en) | Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer |